The Oculis strategy is to build a innovative ophthalmology company unlike any other. Our plan is to:
Our most advanced product candidate based on SNP technology is OCS-01, which recently completed two Phase 2 studies, one in DME and one in Pain and Inflammation following cataract surgery. The study in DME is the first proof-of-concept of a topical drug effect on a chronic retinal disease and is also a successful proof-of-concept for the SNP formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants. The study in post-cataract surgery is the first proof-of-concept of a once daily topical steroid for treating Inflammation and Pain following ocular surgery. OCS-01 is moving into phase III, following a positive End of Phase 2 meeting, in both indications.
Our novel formulation SNP technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
Oculis S.A.has been recognized as one of the Top 100 Swiss Startup companies during the 2020 award ceremony and ranked within the Top 10 Biotech companies. The winners were selected by a jury of 100 leading startup experts and investors and announced during the award ceremony held on September 9, 2020 in Zurich. The TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem: In the last 10 years, the event has featured 397 startups that have created more than 8,700 jobs and raised CHF 4.2 billion. Forty-two exits and two IPOs top off the achievements so far. Each year since 2011, the 100 most innovative and promising Swiss startups are picked by a jury of 100 leading investors and startup experts.